The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium.
 
Preetesh Jain
Honoraria - Kite, a Gilead company; Lilly
Consulting or Advisory Role - Lilly
 
Yucai Wang
Consulting or Advisory Role - Incyte (Inst); Innocare (Inst); Kite, a Gilead company (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Genentech (Inst); Incyte (Inst); InnoCare (Inst); Loxo (Inst); MorphoSys (Inst); Novartis (Inst)
 
Frederick L. Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Celgene; Cellular Biomedicine Group; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Novartis; Sana Biotechnology; Takeda; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Javier Munoz
Honoraria - Kyowa Hakko Kirin; Seagen
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Fosun Kite; Genentech; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Amer Beitinjaneh
Consulting or Advisory Role - Kite, a Gilead company
Research Funding - Atara Biotherapeutics; Kite/Gilead
 
Matthew Joshua Frank
Employment - Roche/Genentech (I)
Stock and Other Ownership Interests - Roche/Genentech (I)
 
Saurabh Dahiya
Consulting or Advisory Role - Atara Biotherapeutics; Kite/Gilead
 
Miriam T. Jacobs
No Relationships to Disclose
 
Brian T Hill
Honoraria - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis; Novartis; Pfizer; Pharmacyclics
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Epizyme; Genentech; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Genentech (Inst); Karyopharm Therapeutics (Inst); Kite/Gilead (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Lazaros J. Lekakis
No Relationships to Disclose
 
David Bernard Miklos
Honoraria - fosun Kite Biotechnology; Janssen
Consulting or Advisory Role - Adaptive Biotechnologies; Janssen; Juno/Celgene; Pharmacyclics
Research Funding - Adaptive Biotechnologies; Adicet Bio; Alimera Sciences; Kite, a Gilead company; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
 
Armin Ghobadi
No Relationships to Disclose
 
Sattva Swarup Neelapu
Honoraria - Aptitude Health; Bio Ascend; Medscape; MJH Life Sciences
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Athenex; Bluebird Bio; Bristol-Myers Squibb; Calibr; Gilead Sciences; Incyte; Kite, a Gilead company; Merck Sharp & Dohme; Novartis; Sana Biotechnology; Sellas Life Sciences
Research Funding - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Cellectis; Gilead Sciences; Kite, a Gilead company; poseida therapeutics; Precision Biosciences; Unum Therapeutics
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy; Royalty income from Takeda Pharmaceuticals
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Pfizer (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)
 
Michael Wang
Honoraria - Acerta Pharma; AstraZeneca; BeiGene; Breast-Gynecological International Cancer Society; CAHON; Chinese Anti-Cancer Association; Chinese Medical Association; Clinical Care Options; Dava Oncology; Epizyme; Hebei Cancer Prevention Federation; Imedex; Janssen Research & Development; Kite, a Gilead company; Miltenyi Biomedicine; Moffit Cancer Center; Mumbai Hematology Group; Newbridge Pharmaceuticals; OM Pharmaceutical Industries; Pharmacyclics/Janssen; Physicans' Education Resource; Scripps Health; The First Affiliated Hospital of Zhejiang University
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; Bioinvent; CStone Pharmaceuticals; DTRM; Epizyme; Genentech; Guidepoint Global; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; Miltenyi Biomedicine; Oncternal Therapeutics; Pharmacyclics/Janssen; Pulse Biosciences; VelosBio
Research Funding - Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Celgene; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Lilly; Loxo; Molecular Templates; Oncternal Therapeutics; Pharmacyclics; VelosBio
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Michael D. Jain
Consulting or Advisory Role - Bristol-Myers Squibb; Kite/Gilead; Novartis; Takeda
Research Funding - Incyte; Kite/Gilead
Travel, Accommodations, Expenses - Kite/Gilead
 
Matthew J. Maurer
Employment - Exact Sciences (I)
Stock and Other Ownership Interests - Exact Sciences (I)
Consulting or Advisory Role - Adaptive Biotechnologies; Genmab; Kite, a Gilead company; MorphoSys; Pfizer
Research Funding - Celgene (Inst); Genentech (Inst); Morphosys (Inst); NanoString Technologies (Inst)